Thomas B. Smith
Known title: EVP and Chief Medical OfficerCIK: 0001748462
Associated companies
Transaction History
| COLL | ▲ Buy | Grant | 14,268 | $0 | 2/10/2026 | View on chart |
| COLL | ▲ Buy | Grant | 22,774 | $0 | 2/10/2026 | View on chart |
| COLL | ▼ Sell | Tax Withholding | 5,897 | $276K | 2/10/2026 | View on chart |
| COLL | ▼ Sell | Tax Withholding | 11,538 | $539K | 2/10/2026 | View on chart |
| COLL | ▼ Sell | Open Market | 17,478 | $672K | 8/29/2025 | View on chart |
| COLL | ▼ Sell | Tax Withholding | 1,498 | $46K | 2/10/2025 | View on chart |
| COLL | ▼ Sell | Tax Withholding | 4,399 | $134K | 2/10/2025 | View on chart |
| COLL | ▲ Buy | Grant | 33,762 | $0 | 2/10/2025 | View on chart |
| COLL | ▲ Buy | Grant | 5,313 | $0 | 2/10/2025 | View on chart |
| COLL | ▼ Sell | Open Market | 9,593 | $351K | 9/13/2024 | View on chart |
| COLL | ▼ Sell | Open Market | 995 | $37K | 2/29/2024 | View on chart |
| COLL | ▼ Sell | Tax Withholding | 1,899 | $64K | 2/12/2024 | View on chart |
| COLL | ▼ Sell | Tax Withholding | 1,300 | $44K | 2/12/2024 | View on chart |
| COLL | ▲ Buy | Grant | 4,623 | $0 | 2/12/2024 | View on chart |
| COLL | ▲ Buy | Grant | 30,800 | $0 | 2/12/2024 | View on chart |
| COLL | ▲ Buy | Grant | 31,185 | $0 | 2/10/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
COLL Outlook Supported by ADHD Trends, Low Generic Risk, Oppenheimer
Oppenheimer notes that Collegium Pharmaceutical's outlook is bolstered by strong demand for ADHD treatments and a low risk of generic competition. The firm’s focus on these areas may help sustain revenue growth. The stock is currently trading near its 52‑week low of $21.43, close to a support level that has been tested repeatedly.
COLL Outlook Supported by ADHD Trends, Low Generic Risk, Oppenheimer. Oppenheimer notes that Collegium Pharmaceutical's outlook is bolstered by strong demand for ADHD treatments and a low risk of generic competition. The firm’s focus on these areas may help sustain revenue growth. The stock is currently trading near its 52‑week low of $21.43, close to a support level that has been tested repeatedly.